Tuberculosis presentation and outcomes in elderly Hispanics from Tamaulipas, Mexico

- 3 Belinda A. Medrano¹, Miryoung Lee ¹, Gretchen Gemeinhardt², Javier E. Rodríguez-Herrera³,
- 4 Moncerrato García-Viveros³, Blanca I. Restrepo ^{1,4,5,*}
- 6 Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public
- 7 Health, University of Texas Health Science Center at Houston, Brownsville campus,
- 8 Brownsville, TX, USA

1

2

5

16

19

21

22

23

- 9 ² Department of Management, Policy and Community Health, School of Public Health,
- 10 University of Texas Health Science Center at Houston, Houston, TX, USA
- ³ Secretaría de Salud de Tamaulipas, Reynosa 88630, Matamoros 87370 and Ciudad Victoria,
- 12 Tamaulipas, México
- ⁴ Population Health Program, Texas Biomedical Research Institute, San Antonio, TX, USA
- ⁵ School of Medicine, South Texas Diabetes and Obesity Institute, University of Texas Rio
- 15 Grande Valley, Edinburg, TX, USA
- * Corresponding author: 1214 W. Schunior, UTRGV-EREBL Bldg, Edinburg, TX 78541
- 18 <u>Blanca.i.restrepo@uth.tmc.edu</u>; Tel.: +01-956-279-3841
- 20 **Running title**: Tuberculosis treatment outcomes in elderly Hispanics

Abstract

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

treatment outcomes

Old people are at high risk of developing and dying from pulmonary infections like tuberculosis (TB), but they are few studies and particularly in Hispanics. To address these gaps, we sought to identify host factors associated with TB and adverse treatment outcomes in old Hispanics by conducting a secondary analysis of TB surveillance data from Tamaulipas, Mexico (2006-2013; n=8,381). Multivariable logistic regressions were assessed for the elderly (ELD, \geq 65 years) when compared to young (YA, 18 to 39 years) and middle-aged adults (MAA, 40 to 64 years). We found that the ELD had features associated with a less complicated TB (e.g. less extrapulmonary TB, abandoning of treatment or having drug resistant TB), and yet, were more likely to die during TB treatment (adj-OR 3.9, 95% 2.5, 5.25). Among the elderly, excess alcohol use and low BMI increased their odds of death, while diabetes and BCG vaccination were protective. These data suggest that old people share some, but not all the risk factors for adverse TB treatment outcomes, when compared with younger adults. Furthermore, even though old age in itself is an important predictor of death during TB, the elderly are not prioritized by the World Health Organization for latent TB infection screening and treatment during contact investigations. We propose the inclusion of the elderly as a high-risk group in TB management guidelines. **Keywords**: tuberculosis, Hispanics, older people, elderly, gerontology, diabetes, BCG, BMI,

Introduction

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

Mycobacterium tuberculosis is a bacterial disease that has infected a quarter of the world's population with non-symptomatic latent infection or progressed to active tuberculosis (TB) disease. In 2020, an estimated 9.9 million people developed TB and 1.5 million died [1]. Latent TB infection and active TB disease are more prevalent in the elderly, i.e., adults over the age of 65 [2-4]. This is relevant as the global elderly population grows from 1 out of 11 in 2019 to 1 in 6 by 2050 [5]. The World Health Organization (WHO) regions of the Eastern Mediterranean, South-East Asia, and Western Pacific already have a significant burden of TB cases in the elderly populations with Taiwan anticipating almost 80% of their new TB cases in the elderly by 2035 [2, 6]. The elderly face additional risks of TB reactivation and infection compared to younger adults, such as compromised immunity, comorbid conditions, and increased TB exposures due to clustering in nursing homes [7-9]. TB and general mortality are highest in the elderly group [2, 10]. An aging population, longer life expectancy, and reactivation of TB disease in the elderly pose challenges to meeting the World Health Organization's 'End TB Strategy' goals of a 90% and 95% reduction in TB incidence and deaths, respectively, by 2035 [1, 8, 10, 11]. Despite their high vulnerability, TB in the elderly is understudied, and the available literature is mostly from Asian populations, with few in Hispanics [12-14]. Studies in Latin American Hispanics are warranted given that risk factors for TB such as poverty, migration, homelessness, incarceration, and diabetes have increased in the last decade [15, 16]. Even in a high-income country like the United States, the TB case rate is nine times higher for Hispanics than for non-Hispanic whites (Centers for Disease Control and Prevention [17].

Given the impact of old age on TB elimination efforts, it is important to study the elderly TB group with the goals of improving patient outcomes and preventing additional TB cases. To address this knowledge gap, and particularly among Hispanics, we aimed to identify sociodemographic and medical risk factors and secular trends for TB in the elderly from the state of Tamaulipas in northeastern Mexico. We also sought to identify the risk factors associated with adverse treatment TB outcomes in old age.

Materials and Methods

Study Population

We conducted a secondary analysis of existing TB surveillance data on adults ages 18 to 99 years with a new TB diagnosis and who were reported to the state of Tamaulipas, Mexico between 2006 and 2013. The state's TB program surveillance dataset was described previously [18]. Briefly, the Tamaulipas's TB surveillance dataset was comprised of 12,748 TB patients enrolled between 2005 and 2013, and we excluded repeat episodes from the same subject (n=1,827), individuals less than 18 years old (n=624), recurring TB cases (n=777), and individuals enrolled in 2005 who had poor data quality (n=1,089). This left 8,431 new adult TB patients [18]. For this study, we further excluded 43 individuals identified as having a previous TB episode and seven with missing data on TB treatment outcomes, for a final sample size of 8,381 TB patients. Patient data was deidentified and the protocol was approved from the Internal Review Board from UTHealth Houston (HSC-SPH-15-0489) and the Secretaría de Salud de Tamaulipas (076/2015/CEI).

Participant Characteristics

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

We compared the elderly group (65 yrs. or older, ELD) to young adults (18-39 yrs., YA) or middle-aged adults (40-64 yrs., MAA). Sociodemographic variables included age, sex, education, Bacille Calmette-Guerin (BCG) vaccination at birth based on the presence of a BCG scar, self-reported excess alcohol use or intravenous (IV) drug use, and low body mass index (BMI <18.5 kg/m² at the time of TB diagnosis). Comorbidities included chronic obstructive pulmonary disease (COPD), self-reported diabetes, and self-reported or laboratory-confirmed HIV. Variables related to TB at the time of diagnosis included disease location (extrapulmonary or pulmonary), positive acid-fast bacilli (AFB) on sputum smears, diagnosis method [culture confirmation by isolation of *M. tuberculosis*, positive AFB smears only, or in their absence, a combination of clinical, epidemiological, radiological and/or histopathological findings], and the number of close contacts. In Mexico, drug susceptibility testing is limited to patients with high suspicion of drug-resistant TB with results available for isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), streptomycin (STR), and ethambutol (EMB). Mycobacterium tuberculosis was classified as drug resistant (DR-TB) if resistant to any of the five TB drugs and multi-drug resistant (MDR-TB) when at least INH and RIF were resistant. The adverse outcomes of interest included TB treatment failure (positive AFB smears after five months of TB treatment), abandoned treatment (lost during follow-up for more than three months), and death due to any cause during TB treatment. **Statistical Analyses** Two-group comparisons of binary variables were analyzed by Pearson's chi-square or Fisher's exact test and the Student's-t test was used for mean comparisons between two groups. Increasing or decreasing trends across age groups or across time were established by the score test for the trend of odds for binary variables. To conduct comparisons between-group, trends

across age groups, and trends across time for polytomous and numerical variables, we used the nptrend command in STATA, which is a nonparametric test for trends across ordered groups (an extension of the Wilcoxon rank-sum test). For multiple logistic regressions models, we used backward selection with consideration of variables with p values less than 0.20 in bivariable analysis, and keeping age and sex as key sociodemographics in final models. Effect modification variables for age and each predictor variable were included in simple logistic regression models for adverse outcomes, to determine if age modifies the observed effect of each predictor variable. Statistical significance was set at Type I error (alpha) level <0.05. Data analysis was performed using STATA IC (Stata Corp LLC, College Station, TX) 14.

Results

110

111

112

113

114

115

116

117

118

119

120

Sociodemographics and Comorbidities in the Elderly

121 The characteristics of the 8,381 TB patients for analysis are described in **Table 1**. Their mean 122 age was 43 years (SD 16.6; range 18 to 97). Males comprised 65.5% of all TB patients. Less than 123 half (42.2%) had a high school degree or higher education, three-fourths (76.2%) had a history of 124 BCG vaccination, 5.6% reported excess alcohol use, 0.5% were IV drug users, and 8.3% had low BMI. The most prevalent comorbidity was diabetes (25.2%), followed by HIV (5.3%) and 125 COPD (0.9%). 126 127 The distribution of TB patients by age group was: 46% in YA, 42% in MAA, and 12% in ELD. Mean ages for YA, MAA, and ELD TB patient groups were 28 (SD 6.2), 50 (SD 6.9), and 73 128 129 (SD 6.5) years, respectively. The ELD differed from the two younger age groups in their lower level of education (high school degree or higher in 10.9% in ELD vs 56.9% in YA or 35.5% in 130 MAA), BCG vaccination (48.8% in ELD vs 83.6% in YA and 75.7% in MAA), and IV drug use 131

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

(0.1% in ELD vs 0.8% in YA). Accordingly, significant trends with older age (from YA to MAA to ELD) included a decrease in education level, BCG vaccination rates, and IV drug use, trend p <0.001 for all. Low BMI was highest in the ELD (10.3%) followed by YA (9.3%) and MAA (6.6%).For comorbidities, COPD was more common among the ELD (4.1% in ELD vs 0.1% in YA and 0.7% in MAA; p <0.001 for increasing trend with older age). Diabetes increased with older age (trend p <0.001), although MAA had the highest prevalence (40%), with the ELD having 31.9% and YA 10% (p <0.001). HIV prevalence was lowest in the ELD (0.5% in ELD vs 7.7% YA and 4.0% in MAA; p <0.001 for decreasing trend with older age). **TB-related Characteristics** Most patients had pulmonary TB (92%) and a positive AFB smear at the time of diagnosis (85.1%; **Table 1**). Cultures are not routinely performed in Tamaulipas, and hence, the diagnosis was mostly based on smear results (79.1%), with only 6.8% being culture-confirmed. Each TB patient had an average of 3.7 close contacts. When compared to YA, the ELD had less extrapulmonary TB (ELD 6.0% vs YA 9.4%; decreasing trend p <0.001) or culture-confirmed TB (ELD 5.5% vs YA 8.0%). The ELD had the highest mean number of close contacts (ELD 4.1 vs 3.7 in YA or 3.6 in MAA). **TB Drug Resistance** Drug susceptibility testing was only available for 1,165 (13.9%) TB patients, with more testing in YA (15.4%) and MAA (14.2%) vs. the ELD (7.3%; trend p <0.001; **Table 2**). For primary analysis, we assumed that the absence of susceptibility results indicated drug-susceptible TB

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

since testing is prompted when DR-TB is suspected (Table 2). We found that DR-TB decreased with age (trend p=0.030). Among all age groups, the highest monoresistance was for INH (1.2%), and across age groups, only INH monoresistance showed a decreasing trend with age (p=0.002). MDR-TB occurred in 0.6% of all patients and did not differ across age groups. Similar analysis but limited to isolates tested for drug resistance provided similar findings (S1 Table). **Adverse TB Treatment Outcomes** Among all patients, 14.9% had one of the following adverse outcomes: treatment failure (1.9%), abandoned treatment (6.9%), or death (6.2%), **Table 1**. Adverse TB treatment outcomes were highest among the ELD (20.1%) followed by YA (15.4%) and MAA (12.9%) groups. Treatment failure did not differ between age groups, but the ELD group was less likely to abandon treatment (4.3%) when compared to YA (9.2%; p < 0.001) with a decreasing trend with older age (trend p <0.001). In contrast, the ELD were more likely to die during TB treatment (13.6%) when compared to YA (4.5%) or MAA (5.8%) with an increasing trend with older age (trend p <0.001). For multivariable analysis, we examined whether old age was independently associated with adverse TB treatment outcomes with YA as the reference group. IV drug use and HIV were excluded as predictor variables due to their low prevalence in the ELD group (Table 3). Age groups were not associated with treatment failure. Instead, among all age groups, adjusted models showed that treatment failure was higher for males, although statistical significance was not reached (adj. OR 1.45, 95% CI 0.99, 2.10), those with positive AFB smears (adj. OR 1.97, 95% CI 1.03, 3.79) or DR-TB, (adj. OR 13.85, 95% CI 9.42, 20.37). Higher education was

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

protective against treatment failure (adj. OR 0.69, 95% CI 0.48, 0.99). Abandoning treatment was 59% lower in the elderly (adj. OR 0.41, 95% CI 0.28, 0.59) when compared to YA (**Table** 3). Among all TB patients, the factors associated with higher odds of abandoning treatment were male sex (adj. OR 2.09, 95% CI 1.65, 2.66), excess alcohol use (adj. OR 1.44, 95% CI 1.03, 2.01), and low BMI (adj. OR 1.59, 95% CI 1.18, 2.13). Protective factors against abandoning treatment included high school or higher education (adj. OR 0.74, 95% CI 0.60, 0.90), having extrapulmonary disease (adj. OR 0.51, 95% CI 0.30, 0.87), and positive AFB smear at diagnosis (adj. OR 0.63, 95% CI 0.49, 0.82). The odds of abandoning treatment decreased by 11% (adj. OR 0.89, 95% CI 0.85, 0.93) for each additional close contact reported by a TB patient. Death was four-fold higher with old age (ELD vs YA: adj. OR 3.90, 95% CI 2.90, 5.25; **Table 3**). Among all TB patients, the odds of death were also higher for MAA (adj. OR 1.62, 95% CI 1.25, 2.09), males (adj. OR 1.59, 95% CI 1.24, 2.04), excess alcohol users (adj. OR 1.66, 95% CI 1.15, 2.39), those with low BMI (adj. OR 2.14, 95% CI 1.60, 2.87), and extrapulmonary disease (adj. OR 1.94, 95% CI 1.29, 2.91). BCG vaccination (adj. OR 0.67, 95% CI 0.53, 0.85), diabetes (adj. OR 0.59, 95% CI 0.44, 0.78), and positive AFB smear (adj. OR 0.63, 95% CI 0.47, 0.84) were protective against death. We sought to identify independent predictors of adverse outcomes among the ELD group alone (S2 Table). In the ELD, the odds of treatment failure was 14 times higher in patients with DR-TB (adj. OR 14.10, 95% CI 4.69, 42.32). Abandoning treatment decreased by 56% for those with a positive AFB smear and by 15% for each close contact. The odds of death increased by 4% for each additional year of life, and by more than 2-fold in those with excess alcohol use or low BMI. Male sex was not associated with any adverse outcome in the ELD (S2 Table), despite its relationship with treatment failure, abandoning treatment and death in all age groups (**Table 3**).

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

Finally, we evaluated if among all TB patients, age would modify the associations between host factors and adverse TB treatment outcomes. However, multivariable models with additional interaction terms for age did not show significant associations (S3 Table). Trends Over the Eight-year Period in the ELD We evaluated if there were trends over time (2006 -- 2013) in the prevalence or characteristics of the ELD group. Among all TB patients, the proportion of ELD remained similar across the years (range 11.2 – 13.8%; p 0.531; **S4 Table**). Among the ELD group only, there was an increasing trend in education level (p < 0.001), BCG vaccination (p < 0.001), diabetes (p 0.010), extrapulmonary TB (p 0.005) and DR-TB (p 0.002; **Tables 4 and S4**). We also evaluated trends over time for younger adults (Table 4) and found that unlike the ELD, the YA and MAA had a reduction in excess alcohol use, low BMI, and abandoning of TB treatment, and that the YA had a decreasing trend in death. **Discussion** Despite projections showing a worldwide increase in the proportion of older individuals, studies in the elderly are underrepresented when compared to those in younger adults [19-21]. This knowledge gap extends to the elderly with TB, especially in the Americas. To address this disparity, we sought to obtain a better understanding of elderly Hispanics with TB using TB surveillance data from the Mexican state of Tamaulipas. The elderly comprised 12.3% of all adult TB patients, and over the eight-year study period we observed: i) an improvement in factors that could be protective for TB (e.g. higher education and BCG vaccination coverage), ii)

an increase in factors that favor adverse TB outcomes (e.g. extrapulmonary TB and DR-TB), and

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

iii) an increase in diabetes, which had a protective effect on TB outcomes in our ELD cohort as discussed below [22-26]. The elderly differed from younger adults in their higher prevalence of COPD, which could increase their odds of a more severe TB disease, and in having less BCG vaccination and lower education level, which have been associated with higher odds of TB [14, 27, 28]. However, old age was also associated with factors known to improve their TB prognoses such as less IV drug use, HIV, and extra-pulmonary TB, and abandonment of treatment [29-31]. The distribution of risk factors for TB, therefore, can have variations across all adult age groups and identifying the high-risk profiles in the elderly is important for prompt TB suspicion, diagnosis, and treatment initiation, in order to improve their prognosis. Regardless of a combination of risk and protective factors for TB in the elderly in multivariable models, the highest threat to this age group was their higher odds of death. This finding is consistent with previous studies in the elderly, and we now report it in our Hispanic TB patients [9, 32]. And among the elderly with TB, death was associated with an increase in age, excess alcohol use and low BMI. These factors also contribute to the higher odds of death in all adult age groups [1, 2, 25, 33, 34]. In contrast, male sex was a risk factor for death in YA and MAA TB patients, but not in the ELD in our study. The prevalence of type 2 diabetes increases with age, as observed in our TB cohort [35, 36]. Diabetes is a risk for TB in adults, this includes findings using prospective or retrospective cohorts from Hispanics in US and Mexican communities [18, 37, 38] but not in older people [13, 14]. We posit that differences between diabetes in younger versus older adults may be explained by differences in the pathophysiology and/or the management of type 2 diabetes [13]. While diabetes in the elderly may not be a risk factor for TB development, in the present study, we evaluated if it would be associated with higher odds of death. We found the opposite, with

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

diabetes being protective, as reported in Brazil by [39]. A higher risk of adverse TB treatment outcomes in the presence of diabetes has been reported in previous studies, although not specifically evaluated in older patients [9, 25, 40]. A possible explanation for these discrepant findings may be the higher prevalence of obesity in diabetes patients. While diabetes is a risk factor for TB, obesity is protective against TB [41, 42]. It is possible that the higher prevalence of obesity in our study population offsets, to some extent, the risk of death during TB that is conferred by diabetes [43]. Consistent with this finding, a study in adults from India reported that diabetes offsets the risk of adverse outcomes conferred by low BMI [44]. Further studies are needed to understand the relationship between diabetes, BMI, death in TB patients, and old age. We found that BCG vaccination at birth decreased with older age. This is consistent with the lower prevalence of BCG vaccination in the elderly versus younger adults with TB in a prospective research cohort [14]. In that study, BCG vaccination at birth was associated with lower odds of TB, but only in the elderly. This finding was intriguing given that BCG is known to protect infants and young children from TB, but not adults [1]. Here we find that BCG vaccination at birth is associated with lower odds of death from TB in all age groups. Our findings are consistent with the association between unfavorable TB treatment outcomes and absence of a BCG scar in a Malaysian population [25]. Together, these findings suggest a possible protective role of BCG with respect to TB risk or death, although further studies are needed to rule out confounding factors that were not available in the surveillance dataset, such as lower access to healthcare in non-BCG-vaccinated individuals. At the cellular level, BCG vaccination induces epigenetic changes in innate immune cells (e.g., trained immunity) that associate with protection against TB and other microbial infections [45]. Thus, basic science

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

studies are also warranted to help elucidate how BCG vaccination at birth may contribute to TB protection and lower the risk of death in the elderly. We found a decreasing prevalence of extrapulmonary TB with older age, which is consistent with previous studies [31, 46]. These age-related differences may be due to a lower prevalence of comorbidities like HIV, when compared to younger TB patients, that favor extrapulmonary disease [31, 46, 47]. Abandonment of treatment contributes to adverse outcomes but we found that the ELD are less likely to abandon TB treatment [30, 48, 49]. Interestingly, we found an inverse association between the number of TB contacts and odds of abandoning treatment in all age groups, or among ELD patients only. Further studies are needed to determine if this finding is consistent with reports indicating that the level and quality of social support received by patients affects their health outcomes and adherence to treatments [50-53]. Patients with drug-resistant TB are more likely to have adverse treatment outcomes [1, 49, 54, 55]. While we found a lower prevalence of DR-TB in the ELD, our findings point to the importance of identifying these patients given their higher odds of treatment failure. Our large sample size, coverage over an eight-year period, and breakdown of age into three groups, allowed for an in-depth cross-sectional assessment of unique features in ELD TB patients with respect to their sociodemographics, comorbidities, TB characteristics, and treatment outcomes. Limitations included the secondary nature of the data analyses. Diabetes diagnosis and duration of disease, excess alcohol use, and, to some extent, HIV status were selfreported and may be underestimated, although we do not anticipate that there would be a differential underreporting of these host characteristics in the ELD when compared to other age

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

groups. Low BMI was reported as a categorical variable with no further granularity to assess the contribution of different levels of body weight or obesity to TB risk or protection in the elderly. Smoking is a risk factor for TB and known to be more prevalent in older cohorts, but not reported in this surveillance dataset [14]. Finally, DR-TB testing was only evaluated upon suspicion, as in most TB-endemic countries worldwide, and hence, pan-susceptibility was assumed when data was not available. However, analysis limited to patients in whom drug susceptibility was tested provided similar results (**Table S1**). Our study raises awareness of the high vulnerability of older people to death from TB. Per WHO's latent TB infection management guidelines, TB contact investigations focus on the identification of high-risk groups for TB development. However, these are limited to children below 5 years of age or people living with HIV, and of other adults and children household contacts in low TB incidence countries without mention of the growing elderly population [56]. Our findings call for the need to consider the elderly in a similar high-risk category. A recent study showed that Interferon-gamma release assays (IGRA) are effective for identification of latent TB infection in the elderly [57]. We also identified modifiable sociodemographic factors associated with higher odds of death during TB in the elderly, such as excess alcohol use or low BMI. Close supervision of elderly with new TB or LTBI should be offered for counseling of alcohol use or nutritional support. We also found that abandoning treatment was more likely when patients have fewer contacts. Hence, protocols to promote social workers at TB clinics to reach out to family members to emphasize the importance of social support, can have a positive impact on treatment success. By studying the elderly TB group separately from the other distinct adult age groups, we will have a better understanding of how to approach the challenges of TB eradication in this understudied and vulnerable population.

Acknowledgements

We thank the personnel from all the sanitary jurisdictions of the Secretaría de Salud de

Tamaulipas who contributed to the collection and recording of data from the TB patients, and Dr.

Santa Elizabeth Ceballos Liceaga for providing the surveillance datasets for our analysis as

coordinator of the Sistema de Vigilancia Epidemiológica de Tuberculosis y Lepra, Dirección

General de Epidemiología, Secretaría de Salud de Mexico. We also thank Dr. Bassent Abdelbary

for generation of the basic dataset used for analysis and guidance for data analysis.

References

317

318

- 319 1. World-Health-Organization. Global tuberculosis report 2021.
- 320 https://wwwwhoint/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-
- 321 <u>2021</u> [Internet]. 2021 2022. Available from: https://www.who.int/teams/global-tuberculosis-
- 322 programme/tb-reports/global-tuberculosis-report-2021.
- 2. Caraux-Paz P, et al. Tuberculosis in the Elderly. J Clin Med. 2021;10(24).
- 324 3. Hochberg NS, Horsburgh CR, Jr. Prevention of tuberculosis in older adults in the United
- States: obstacles and opportunities. Clin Infect Dis. 2013;56(9):1240-1247.
- 4. Li T, et al. Age-Specific Pulmonary Tuberculosis Notification Rates China, 2008-2018.
- 327 China CDC Wkly. 2022;4(38):841-846.
- World population aging 2019. New York, NY, USA: United Nations, 2020 2020. Report
- No. Available from:
- 330 https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationA
- 331 geing2019-Report.pdf.
- Ku CC, Dodd PJ. Forecasting the impact of population ageing on tuberculosis incidence.
- 333 PLoS One. 2019;14(9):e0222937.
- 7. Chitnis AS, et al. Trends in Tuberculosis Cases Among Nursing Home Residents,
- California, 2000 to 2009. J Am Geriatr Soc. 2015;63(6):1098-1104.

- 8. Murali S, et al. Comparison of profile and treatment outcomes between elderly and non-
- elderly tuberculosis patients in Puducherry and Tamil Nadu, South India. PLoS One.
- 338 2021;16(8):e0256773.
- Negin J, et al. Tuberculosis among older adults--time to take notice. Int J Infect Dis.
- 340 2015;32:135-137.
- 341 10. Di Gennaro F, et al. Active Pulmonary Tuberculosis in Elderly Patients: A 2016-2019
- Retrospective Analysis from an Italian Referral Hospital. Antibiotics (Basel). 2020;9(8).
- 343 11. Cheng J, et al. Incidence and risk factors of tuberculosis among the elderly population in
- China: a prospective cohort study. Infect Dis Poverty. 2020;9(1):13.
- 345 12. Garcia-Goez JF, et al. Tuberculosis in elderly patients in the city of Cali, Colombia: a
- hospital-based cohort study. J Bras Pneumol. 2020;46(5):e20200072.
- 347 13. Restrepo BI, et al. Differential Role of Type 2 Diabetes as a Risk Factor for Tuberculosis
- in the Elderly versus Younger Adults. Pathogens. 2022;11(12).
- 349 14. Scordo JM, et al. A prospective cross-sectional study of tuberculosis in elderly Hispanics
- reveals that BCG vaccination at birth is protective whereas diabetes is not a risk factor. PLoS
- 351 One. 2021;16(7):e0255194.
- 352 15. Tuberculosis in the Americas. Regional Report 2020. Washington D.C: Pan American
- Health Organization (PAHO), 2021 2021. Report No. Available from:
- 354 https://iris.paho.org/handle/10665.2/55194.

- 355 16. Ranzani OT, et al. Increasing tuberculosis burden in Latin America: an alarming trend for
- global control efforts. BMJ Glob Health. 2021;6(3).
- 357 17. CDC. TB and Hispanic or Latino Persons. Centers for Disease Control and Prevention,
- 358 2022 11/22/2022. Report No. Available from:
- 359 https://www.cdc.gov/tb/topic/populations/latino/default.htm.
- 360 18. Abdelbary BE, et al. Tuberculosis-diabetes epidemiology in the border and non-border
- regions of Tamaulipas, Mexico. Tuberculosis (Edinb). 2016;101S:S124-S134.
- 362 19. Mody L, et al. Recruitment and retention of older adults in aging research. J Am Geriatr
- 363 Soc. 2008;56(12):2340-2348.
- World population aging 2020 Highlights. New York: United Nations, 2020 2020. Report
- 365 No. Available from:
- 366 https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/docu
- ments/2020/Nov/undesa_pd-2020_world_population_ageing_highlights.pdf.
- 368 21. World-Health-Organization. Ageing and health. World Health Organization; WHO, 2022
- 369 10/1/2022. Report No. Available from: https://www.who.int/news-room/fact-
- 370 <u>sheets/detail/ageing-and-health.</u>
- 371 22. Atif M, et al. Treatment outcomes of extrapulmonary tuberculosis in Bahawalpur,
- Pakistan; a record review. J Pharm Policy Pract. 2020;13:35.

- 373 23. Gebrezgabiher G, et al. Treatment Outcome of Tuberculosis Patients under Directly
- Observed Treatment Short Course and Factors Affecting Outcome in Southern Ethiopia: A Five-
- 375 Year Retrospective Study. PLoS One. 2016;11(2):e0150560.
- 376 24. Koch A, et al. Drug-resistant tuberculosis: challenges and opportunities for diagnosis and
- treatment. Curr Opin Pharmacol. 2018;42:7-15.
- 378 25. Tok PSK, et al. Determinants of unsuccessful treatment outcomes and mortality among
- tuberculosis patients in Malaysia: A registry-based cohort study. PLoS One.
- 380 2020;15(4):e0231986.
- 381 26. Yen YF, et al. Determinants of mortality in elderly patients with tuberculosis: a
- population-based follow-up study. Epidemiol Infect. 2017;145(7):1374-1381.
- 383 27. Jain VK, et al. Tuberculosis in the era of COVID-19 in India. Diabetes Metab Syndr.
- 384 2020;14(5):1439-1443.
- Nordholm AC, et al. Social determinants of tuberculosis: a nationwide case-control study,
- 386 Denmark, 1990-2018. Int J Epidemiol. 2022;51(5):1446-1456.
- 29. Lienhardt C. From exposure to disease: the role of environmental factors in susceptibility
- to and development of tuberculosis. Epidemiol Rev. 2001;23(2):288-301.
- 389 30. Mansour G, et al. Factors Related to Non-Adherence and Abandonment of Pulmonary
- Tuberculosis Treatment. Medicina (Ribeirao Preto). 2021;54(2):e-172543.

- 391 31. Qian X, et al. Risk factors for extrapulmonary dissemination of tuberculosis and
- associated mortality during treatment for extrapulmonary tuberculosis. Emerg Microbes Infect.
- 393 2018;7(1):102.
- 394 32. Leung EC, et al. Delayed diagnosis of tuberculosis: risk factors and effect on mortality
- among older adults in Hong Kong. Hong Kong Med J. 2018;24(4):361-368.
- 396 33. Rehm J, et al. The association between alcohol use, alcohol use disorders and
- tuberculosis (TB). A systematic review. BMC Public Health. 2009;9:450.
- 398 34. Volkmann T, et al. Tuberculosis and excess alcohol use in the United States, 1997-2012.
- 399 Int J Tuberc Lung Dis. 2015;19(1):111-119.
- 400 35. CDC. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the
- 401 United States. Atlanta, GA, USA: Centers for Disease Control and Prevention, 2022 6/29/2022.
- 402 Report No. Available from: https://www.cdc.gov/diabetes/data/statistics-report/index.html.
- 403 36. Mordarska K, Godziejewska-Zawada M. Diabetes in the elderly. Prz Menopauzalny.
- 404 2017;16(2):38-43.
- 405 37. Al-Rifai RH, et al. Association between diabetes mellitus and active tuberculosis: A
- systematic review and meta-analysis. PLoS One. 2017;12(11):e0187967.
- 407 38. Restrepo BI, et al. Cross-sectional assessment reveals high diabetes prevalence among
- 408 newly-diagnosed tuberculosis cases. Bull WHO. 2011;89(5):352-359.

- 409 39. Evangelista M, et al. Tuberculosis associated with diabetes mellitus by age group in
- 410 Brazil: a retrospective cohort study, 2007-2014. Braz J Infect Dis. 2020;24(2):130-136.
- 411 40. Reed GW, et al. Impact of diabetes and smoking on mortality in tuberculosis. PLoS ONE.
- 412 2013;8(2):e58044.
- 413 41. Harries AD. Having diabetes and being underweight in Asia: a potent risk factor for
- 414 tuberculosis. Int J Tuberc Lung Dis. 2019;23(12):1237-1238.
- 415 42. Lin HH, et al. Association of Obesity, Diabetes, and Risk of Tuberculosis: Two
- 416 Population-Based Cohorts. Clin Infect Dis. 2018;66(5):699-705.
- 417 43. Restrepo BI, et al. Diabetes screen during tuberculosis contact investigations highlights
- opportunity for diabetes diagnosis and reveals metabolic differences between ethnic groups.
- 419 Tuberculosis (Edinb). 2018;113:10-18.
- 420 44. Kornfeld H, et al. Impact of Diabetes and Low Body Mass Index on Tuberculosis
- Treatment Outcomes. Clin Infect Dis. 2020;71(9):e392-e398.
- 422 45. Netea MG, et al. Defining trained immunity and its role in health and disease. Nat Rev
- 423 Immunol. 2020;20(6):375-388.
- 424 46. Pang Y, et al. Epidemiology of Extrapulmonary Tuberculosis among Inpatients, China,
- 425 2008-2017. Emerg Infect Dis. 2019;25(3):457-464.

- 426 47. Shivakoti R, et al. Association of HIV infection with extrapulmonary tuberculosis: a
- 427 systematic review. Infection. 2017;45(1):11-21.
- 428 48. CDC. Basic TB facts. Atlanta, GA, USA: Centers for Disese Control and Prevention,
- Division of Tuberculosis Elimination NCfH, Viral Hepatitis, STD, and TB Prevention; 2016
- 430 03/20/2016. Report No. Available from: https://www.cdc.gov/tb/topic/basics/default.htm.
- 431 49. Trebucq A, et al. Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade
- 432 of Evidence. J Clin Med. 2019;9(1).
- 433 50. Boen CE, et al. Social Relationships, Inflammation, and Cancer Survival. Cancer
- 434 Epidemiol Biomarkers Prev. 2018;27(5):541-549.
- 435 51. Cayla JA, et al. Tuberculosis treatment adherence and fatality in Spain. Respir Res.
- 436 2009;10(1):121.
- 437 52. Li X, et al. Effectiveness of comprehensive social support interventions among elderly
- patients with tuberculosis in communities in China: a community-based trial. J Epidemiol
- 439 Community Health. 2018;72(5):369-375.
- 440 53. World-Health-Organization. Adherence to long-term therapies: evidence for action.
- World Health Organization; WHO, 2003 2003. Report No. Available from:
- https://apps.who.int/iris/handle/10665/42682.

443 54. Abdelbary BE, et al. Predicting treatment failure, death and drug resistance using a

computed risk score among newly diagnosed TB patients in Tamaulipas, Mexico. Epidemiol

445 Infect. 2017;145(14):3020-3034.

444

453

454

455

456

- 446 55. Giri VP, et al. The Characteristics and Patterns of Drug-Resistant Pulmonary
- Tuberculosis in Eastern India. Trop Med Infect Dis. 2022;7(9).
- 448 56. World-Health-Organization. Latent tuberculosis infection: updated and consolidated
- 449 guidelines for programmatic management. World Health Organization; WHO, 2018 2018.
- 450 Report No. Available from: https://apps.who.int/iris/handle/10665/260233.
- 451 57. Scordo JM, et al. Interferon Gamma Release Assays for Detection of Latent
- Mycobacterium tuberculosis in Elderly Hispanics. Int J Infect Dis. 2021.

Supporting Information

- 457 S1 Table. TB drugs susceptibility sub-analysis that excludes not tested and unknown from
- 458 drug resistance calculations.
- 459 S2 Table. Multivariable analyses for predicting treatment failure, abandoned treatment,
- and death in the elderly (ELD) group.
- S3 Table. Evaluation of age as an effect modifier of the association between the predictor
- variables listed and adverse TB outcomes.
- 463 S4 Table. Trends over time (2006 2013) in the prevalence of the Elderly group or their
- 464 characteristics.

Table 1. Descriptive Characteristics of TB Patients by Age Group, Tamaulipas 2006 - 2013

	All Adults	YA	MAA	ELD	ELD vs.	ELD vs.	Trend Across
	(≥ 18 y)	(18 - 39 y)	(40 - 64 y)	(≥65 y)	YA	MAA	Age Groups ^a
Total n (row %)	8381 (100)	3854 (46.0)	3492 (41.7)	1035 (12.3)	p-value ^a	p-value ^a	p-value ^{b, †}
Sociodemographic Character	istics						
Age	43 (16.6)	28 (6.2)	50 (6.9)	73 (6.5)			
Male Sex	5493 (65.5)	2554 (66.3)	2287 (65.5)	652 (63.0)	0.049	0.139	0.068
High School or Higher	3395 (42.2)	2093 (56.9)	1194 (35.5)	108 (10.9)	< 0.001	< 0.001	↓ <0.001
(n=8040)	3393 (42.2)	2093 (30.9)	1194 (33.3)	108 (10.9)	<0.001	<0.001	↓ <0.001
BCG Vaccination (n=7814)	5955 (76.2)	3052 (83.6)	2453 (75.7)	450 (48.8)	< 0.001	< 0.001	↓ <0.001
Excess Alcohol	473 (5.6)	198 (5.1)	236 (6.8)	39 (3.8)	0.069	< 0.001	0.995
IV Drug Use	39 (0.5)	30 (0.8)	8 (0.2)	1 (0.1)	0.013	0.694	↓ <0.001
Low BMI	696 (8.3)	360 (9.3)	229 (6.6)	107 (10.3)	0.333	< 0.001	0.275
Comorbidities							
COPD	72 (0.9)	5 (0.1)	25 (0.7)	42 (4.1)	< 0.001	< 0.001	↑ <0.001
Diabetes	2111 (25.2)	386 (10.0)	1395 (40.0)	330 (31.9)	< 0.001	< 0.001	↑<0.001
HIV	442 (5.3)	297 (7.7)	140 (4.0)	5 (0.5)	< 0.001	< 0.001	↓ <0.001
TB-related Characteristics							

TB Location (n=8380)

Extrapulmonary TB	670 (8.0)	362 (9.4)	246 (7.0)	62 (6.0)	0.001	0.237	↓ <0.001
Pulmonary TB	7710 (92.0)	3491 (90.6)	3246 (93.0)	973 (94.0)			
Positive AFB Smear (n=7683)	6537 (85.1)	2934 (83.7)	2781 (86.1)	822 (86.9)	0.016	0.520	↑ 0.002
TB Diagnosis Type							
Culture confirmation	571 (6.8)	308 (8.0)	206 (5.9)	57 (5.5)	0.017	0.195	0.794
AFB Smear only	6631 (79.1)	2957 (76.7)	2841 (81.4)	833 (80.5)			
Clinical-epidemiological ^c	1145 (13.7)	571 (14.8)	436 (12.5)	138 (13.3)			
Missing	34 (0.4)	18 (0.5)	9 (0.3)	7 (0.7)			
No. of Contacts (n=8103)	3.7 (2.6)	3.7 (2.4)	3.6 (2.5)	4.1 (3.1)	< 0.001	< 0.001	0.220
Adverse treatment Outcomes	1252 (14.9)	592 (15.4)	452 (12.9)	208 (20.1)	< 0.001	< 0.001	0.097
Treatment Failure	156 (1.9)	64 (1.7)	69 (2.0)	23 (2.2)	0.225	0.622	0.176
Abandoned Treatment	579 (6.9)	356 (9.2)	179 (5.1)	44 (4.3)	< 0.001	0.253	↓ <0.001
Died	517 (6.2)	172 (4.5)	204 (5.8)	141 (13.6)	< 0.001	< 0.001	↑ <0.001

Note: Data expressed as number (column %) for categorical variables and mean (standard deviation) for continous variables and number of Contacts.

Analysis of each variable includes all 8,381 TB patients except when indicated in parenthesis. YA=young adults, MAA=middle-aged adults,

ELD=elderly

^a Chi-square test or Fisher's Exact test for categorical variables and Student t test for continuous variables

^b Score test for trend of odds for categorical variables and the nonparametric test for trend across ordered groups, an extension of the Wilcoxon ranksum test, was used for comparing the number of contacts across groups

^c Clinical-epidemiological diagnosis is based on signs and symptoms, epidemiology, radiological and/or histological findings

[†] Trend direction with respect to old age is indicated	d by arrows preceding the trend p values	S	

Table 2. TB Drug Resistance Prevalence by Age Group

	AD A 1 1/	3 7.4	3.7.4.4	ELD	Trend across
	All Adults	YA	MAA	ELD	age groups
	(≥ 18 y)	(18 - 39 y)	(40 - 64 y)	(≥65 y)	p-value ^{b,†}
Total n	8381	3854	3492	1035	
Tested	1165 (13.9)	593 (15.4)	496 (14.2)	76 (7.3)	↓ <0.001
DR-TB	257 (3.1)	134 (3.5)	99 (2.8)	24 (2.3)	↓0.030
INH	99 (1.2)	57 (1.5)	39 (1.1)	3 (0.3)	↓0.002
RIF	6 (0.1)	4 (0.1)	2 (0.1)	0 (0)	0.238
PZA	6 (0.1)	2 (0.1)	3 (0.1)	1 (0.1)	0.544
STR	36 (0.4)	12 (0.3)	17 (0.5)	7 (0.7)	0.083
EMB	4 (0.1)	3 (0.1)	0 (0)	1 (0.1)	0.633
MDR-TB	54 (0.6)	26 (0.7)	22 (0.6)	6 (0.6)	0.715

Note: Data expressed as n (column %). Total n = Total number of TB patients in each age group. This is the denominator for all calculations where those not tested were considered drug-susceptible as described in the text. YA=young adults, MAA=middle-aged adults, ELD=elderly. Tested = susceptibility testing documented. DR-TB= resistant to any of the TB drugs listed. Mono-resistance is listed for individual antibiotics: INH= isoniazid, RIF= rifampin, PZA= pyrazinamide, STR= streptomycin, EMB= ethambutol. MDR-TB=multi-drug resistant TB defined as resistant to at least INH and RIF.

^a Chi-square or Fisher's Exact test

^b Score test for trend of odds across the three age groups

[†] Trend direction with respect to old age is indicated by arrows preceding the trend p values

Table 3. Multivariable analyses to identify whether old age (ELD) is an independent predictor of treatment failure, abandoned treatment, or death

treatment fanure, abandon		,		ndoned		
	Treatment Failure		Treatment		Died	
Predictor Variables	adj. OR	95% CI	adj. OR	95% CI	adj. OR	95% CI
Age Group						
YA (18 - 39 y)	1.00		1.00		1.00	
MAA (40 - 64 y)	1.23	0.85, 1.77	0.49	0.40, 0.61	1.62	1.25, 2.09
ELD (≥65 y)	1.39	0.83, 2.33	0.41	0.28, 0.59	3.90	2.90, 5.25
Sociodemographic Charact	eristics					
Male Sex	1.45	0.99, 2.10	2.09	1.65, 2.66	1.59	1.24, 2.04
High School or Higher	0.69	0.48, 0.99	0.74	0.60, 0.90		
BCG Vaccination					0.67	0.53, 0.85
Excess Alcohol			1.44	1.03, 2.01	1.66	1.15, 2.39
Low BMI			1.59	1.18, 2.13	2.14	1.60, 2.87
Comorbidities						
COPD						
Diabetes					0.59	0.44, 0.78
TB-related Characteristics						
Extrapulmonary TB			0.51	0.30, 0.87	1.94	1.29, 2.91
Positive AFB Smear	1.97	1.03, 3.79	0.63	0.49, 0.82	0.63	0.47, 0.84
No. of Contacts			0.89	0.85, 0.93		
DR-TB	13.85	9.42, 20.37				

Note: Predictor variables with a significance level <0.20 were included in the initial full models. Reduced models (shown) include age group plus predictor variables with a significance level <0.05. adj. OR=adjusted odds ratio. CI=confidence intervals, YA=young adults, MAA=middle-aged adults, ELD=elderly

Table 4. Trends across time (2006--2013) in sociodemographic and clinical characteristics of TB patients by age groups ^{a,†}

	All Adults	YAA	MAA	ELD
	(≥ 18 y) 8381	(18 - 39 y) 3854	(40 - 64 y) 3492	(≥65 y)
	(100%)	(46.0%)	(41.7%)	1035 (12.3%)
Sociodemographic Characteristics				
Male Sex High School or Higher Education	↓0.043	0.070	0.218	0.982
(n=8040)	↑ <0.001	↑ <0.001	^ <0.001	↑ <0.001
BCG Vaccination (n=7814)	^ <0.001	↑ <0.001	^ <0.001	↑0.001
Excess Alcohol	↓ <0.001	↓ <0.001	↓ <0.001	0.168
Low BMI	↓<0.001	↓ 0.004	↓ <0.001	0.158
Comorbidities				
COPD	0.663	0.065	0.844	0.791
Diabetes	^ <0.001	↑0.028	↑0.009	↑0.010
TB-related Characteristics				
Extrapulmonary TB (n=8380)	^ <0.001	0.060	↑0.022	↑0.005
Positive AFB Smear (n=7683)	^ <0.001	↑ <0.001	↑ <0.001	0.179
DR-TB	^ <0.001	↑ <0.001	↑ <0.001	↑0.002
No. of Contacts (n=8103)	↑0.017	↑0.007	0.910	0.090
All adverse treatment Outcomes	↓0.001	↓ <0.001	0.256	0.308
Treatment Failure	0.976	0.318	0.539	0.525
Abandoned Treatment	↓ <0.001	↓0.003	↓0.028	0.789
Died	0.278	↓0.004	0.934	0.283

Note: n indicated in parenthesis for variables with missing data. DR-TB= resistant to any of the TB drugs tested (i.e. isoniazid, rifampin, pyrazinamide, streptomycin, ethambutol)

^a p values shown for the score test for trend of odds for categorical variables, and for the nonparametric test for trend across ordered groups, for number of contacts

[†] Trend direction with respect to old age is indicated by arrows preceding the trend p values